Viking Therapeutics (VKTX) reported late Wednesday a Q1 net loss of $0.41 per diluted share, compared with a loss of $0.26 a year earlier.
Analysts polled by FactSet expected a loss of $0.33.
No revenue was reported for the quarter ended March 31. The company held cash, cash equivalents, and short-term investments of $851.9 million at March 31, compared with $902.6 million on December 31, 2024.
The company's shares were down more than 1% in recent after-market activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。